ARA-290 Research Guide: Cibinetide and Innate Repair

ARA-290, also known by its generic name cibinetide, is an 11-amino-acid peptide engineered from the structure of erythropoietin (EPO). Unlike EPO itself, it was designed to have no red-blood-cell-raising activity at all. Its interest comes from a specific hypothesis: that EPO carries two separable functions, driven by two different receptors — one that builds red blood cells, and a second, injury-induced receptor that limits inflammation and supports tissue repair — and that a small peptide copied from the right part of the EPO molecule can engage only the second system. This guide reviews where that hypothesis came from, what the animal and human studies found, what they did not establish, and what to check analytically before working with the material.

The human record is real but small: exploratory studies in sarcoidosis-associated small fiber neuropathy and one phase 2 study in type 2 diabetes, mostly short and built around surrogate measures such as corneal nerve imaging. There is no phase 3 program and no regulatory approval for any use.

What Is ARA-290?

ARA-290 is a synthetic peptide of 11 amino acids modeled on the aqueous-facing surface of helix B of erythropoietin, the region spanning residues 58–82 of the EPO protein. In the review literature it also appears as pyroglutamate helix B surface peptide, abbreviated pHBSP, because its first residue is pyroglutamate rather than a free N-terminal amino acid. Its development name was ARA 290; cibinetide is the generic name used in the later clinical literature, and the two names refer to the same molecule.

• Sequence: pyroglutamate–Glu–Gln–Leu–Glu–Arg–Ala–Leu–Asn–Ser–Ser (11 residues)
• Also known as: cibinetide; pHBSP (pyroglutamate helix B surface peptide)
• Molecular weight: approximately 1,257.3 g/mol
• Origin: engineered from the helix-B surface of human erythropoietin
• Defining property in the literature: nonerythropoietic — it does not stimulate red blood cell production in the assays reported

Two structural points matter. First, ARA-290 is not a fragment cut from EPO in sequence order: its residues are adjacent in the folded, three-dimensional surface of helix B, assembled to reproduce a shape rather than copy a continuous stretch of the protein. Second, the N-terminal pyroglutamate is part of the specified molecule — a peptide with a different N-terminus is a different compound, a point that returns in the analytical section below.

From Erythropoietin to Helix B

Erythropoietin is best known as the hormone that regulates red blood cell production, but a long line of work, mostly in animal models, found that locally produced EPO also limits damage in injured tissues, including the nervous system, retina, kidney and skin. The problem for research is that giving EPO engages both systems at once, so its blood effects confound its tissue effects.

The study that produced ARA-290 addressed that problem directly. In 2008, Brines and colleagues reported in Proceedings of the National Academy of Sciences that the two functions are mediated by distinct receptors: erythropoiesis through the EPO receptor homodimer, and tissue protection through a heterocomplex of the EPO receptor with CD131, the beta common receptor. Working from EPO's tertiary structure, the group delimited the tissue-protective activity to short peptide sequences. Helix B, which faces the surrounding fluid when EPO sits on its blood-forming receptor, was protective on its own, and an 11-amino-acid peptide reproducing the aqueous face of helix B was also tissue protective in models including ischemic stroke, retinal edema, peripheral nerve trauma and renal ischemia–reperfusion. Neither helix B nor the 11-mer was erythropoietic in vitro or in vivo. That 11-mer is ARA-290.

The Innate Repair Receptor Concept

Brines and Cerami formalized the receptor model in a 2012 Molecular Medicine review, under the name later papers adopted: the innate repair receptor, or IRR. In their account, tissue injury, hypoxia and metabolic stress trigger an innate immune response driven by mediators such as tumor necrosis factor-alpha — a response that clears threats but also enlarges the lesion. Locally produced EPO acts as a compensatory brake, switching on anti-inflammatory and anti-apoptotic programs that delimit injury and allow repair to begin.

Three features distinguish the proposed IRR from the classical blood-forming receptor, and each one shapes how ARA-290 experiments should be interpreted:

• Composition: the erythropoietic receptor is an EPO receptor homodimer; the tissue-protective complex pairs the same EPO receptor subunit with CD131, the beta common receptor shared by several cytokine receptors. In some tissues, additional subunits — the vascular endothelial growth factor receptor in endothelium was the example given — may also participate.
• Expression pattern: the IRR is generally not functional in uninjured tissue. It is induced rapidly by injury and inflammation around a lesion, while EPO production itself is delayed, transient and relatively weak.
• Pharmacological consequence: because the two receptors are different complexes, a ligand can in principle be selective for one of them. ARA-290 was designed as exactly that — intended to activate only the tissue-protective complex and leave the erythropoietic receptor alone.

The model also addresses a pharmacokinetic puzzle. As Collino and colleagues summarized in Pharmacology & Therapeutics in 2015, ARA-290 clears from plasma very quickly — a half-life of about two minutes is reported — yet its effects in animal models persist for weeks after administration stops. The authors interpret the peptide as flipping a molecular switch: a brief receptor engagement initiating a sustained program of cellular change. That is an interpretation offered by the developing group, not a settled mechanism — the duration mismatch is the documented observation, and the switch model is the explanation proposed for it.

The IRR is a well-specified, published hypothesis with supporting experiments, developed largely by one collaborating network — Brines, Cerami and their colleagues — and by companies founded to develop these compounds. Independent replication exists for some individual findings, discussed below, but the framework has not been adopted as settled textbook physiology.

Preclinical Evidence

Nerve injury and spinal inflammation

In the founding 2008 study, helix-B peptides were protective in models of ischemic stroke, retinal edema, peripheral nerve trauma and renal ischemia–reperfusion, and the 11-mer also accelerated wound healing and improved cognitive performance measures in rodents. A focused nerve study followed in 2014, when Swartjes and colleagues examined ARA-290 in rats after spared nerve injury, a standard neuropathic pain model. They reported reductions in mechanical and cold allodynia persisting up to 20 weeks after a short course of treatment early after injury, alongside a suppressed spinal microglial response (Iba-1 immunoreactivity), with no change in the astrocyte marker GFAP. The coupling is suggestive of a central anti-inflammatory component, but it remains a single-model rodent result — allodynia in rats is not a demonstration of pain relief in people.

Immune cells and experimental colitis

One of the more useful preclinical papers came from outside the original development network. In 2017, Nairz and colleagues reported in Scientific Reports that cibinetide, like EPO, ameliorated dextran sulphate sodium-induced colitis in mice, with preserved tissue integrity and reduced infiltration of myeloid cells and production of pro-inflammatory mediators. In lipopolysaccharide-activated primary macrophages, the anti-inflammatory effect depended on CD131 and JAK2 function, and was mediated through inhibition of the NF-kappaB subunit p65 — direct support, from an independent laboratory, for the claim that the peptide's immune effects run through the CD131-containing receptor. Retinal work points the same direction: a 2019 Experimental Eye Research study found that cibinetide enhanced the vasoreparative potential of endothelial colony-forming cells in the ischemic retina.

In sum, the preclinical record shows a peptide active in multiple injury models, with at least some immune effects requiring CD131, and no red-cell effect in the systems tested. It does not establish which model, if any, predicts a human outcome.

Human Trial Evidence

Sarcoidosis-associated small fiber neuropathy: the pilot study

The first human efficacy study was a randomized, double-blind, placebo-controlled pilot by Heij and colleagues in Molecular Medicine in 2012, enrolling 22 patients with sarcoidosis and symptoms of small fiber neuropathy over four weeks. The ARA-290 group improved significantly more than placebo on the Small Fiber Neuropathy Screening List score, and on the pain and physical functioning dimensions of the SF-36; mean pain and fatigue scores, however, improved equally in both groups, and depressive symptoms did not change. No safety concerns were raised in this small sample. The authors' own framing — a pilot, exploratory trial — is the correct one.

Sarcoidosis: symptoms and corneal nerve fibers

Dahan and colleagues followed in 2013 with a second blinded, placebo-controlled trial in sarcoidosis-associated small nerve fiber loss, treated for 28 days. Alongside improved patient-reported symptoms, the ARA-290 group showed a significant increase in corneal small nerve fiber density by corneal confocal microscopy, changes in cutaneous temperature sensitivity, and increased exercise capacity on the six-minute walk test — a quantifiable, structural measure moving in the same direction as the symptom reports.

The largest study extended that design. Culver and colleagues reported a phase 2b, 28-day randomized trial of 64 subjects with sarcoidosis-associated small nerve fiber loss and neuropathic pain in Investigative Ophthalmology & Visual Science in 2017, with change in corneal nerve fiber area as the primary endpoint. One of the three cibinetide groups showed a significant placebo-corrected increase in corneal nerve fiber area at day 28; the other two did not. Regenerating intraepidermal fibers (GAP-43 positive) increased in the same middle group, and corneal changes correlated with changes in those skin fibers and with six-minute walk performance. Pain improved in all groups, including placebo.

Read as a program, the sarcoidosis work is consistent — symptom scores and corneal imaging tended to move together — and clearly exploratory, as a 2014 review by van Velzen and colleagues in Expert Opinion on Investigational Drugs also concluded.

Type 2 diabetes: metabolic control and neuropathy

The second human setting was type 2 diabetes with painful neuropathy. In a phase 2 study by Brines and colleagues in Molecular Medicine in 2015, subjects received ARA-290 or placebo for 28 days and were followed for a further month. No safety issues were identified. The ARA-290 group showed improvements in HbA1c and lipid profiles across the 56-day observation period, and neuropathic symptoms on the PainDetect questionnaire improved significantly. Corneal nerve fiber density increased significantly in the subgroup of treated subjects whose baseline density was more than one standard deviation below normal, with no change in the corresponding placebo subgroup. The authors concluded that ARA-290 deserved continued clinical evaluation — a conclusion the study's size and duration support, and no stronger one.

What the Evidence Does Not Show

• No large or long trials: the human studies are pilots and phase 2 trials, the largest enrolling 64 subjects, with treatment periods of about four weeks. There is no long-term outcome data and no trial powered for hard clinical endpoints.
• No approvals: ARA-290 / cibinetide is not an approved medicine for sarcoidosis, diabetic neuropathy, metabolic disease or any other condition, in any jurisdiction covered by this literature. Every human use described above was investigational, inside a registered trial.
• Surrogate endpoints dominate: corneal nerve fiber density and area, screening-list scores and questionnaires are the measures that moved. Whether corneal imaging changes translate into durable, clinically meaningful benefit is precisely what larger trials would have needed to test.
• Concentrated authorship: most of the human and mechanistic literature originates with the compound's developers and their collaborators. The independent colitis study is a genuine preclinical exception, but there is no independent clinical replication of the sarcoidosis or diabetes findings.
• No basis for extrapolation: nothing in this record speaks to other conditions or any use outside the studied populations, and preclinical breadth — stroke, kidney, retina, colon — should not be read as clinical breadth.

Analytical and Testing Notes

For an 11-amino-acid peptide, identity testing is not a formality. A single deleted residue, a truncated sequence or an incompletely formed N-terminal pyroglutamate produces a product close in size to the target — and not ARA-290.

• Identity by mass spectrometry: the observed molecular mass should match the expected mass of the full 11-residue peptide, approximately 1,257.3 Da, including the N-terminal pyroglutamate. A mass short by one residue, or consistent with a free glutamine or glutamate N-terminus instead of pyroglutamate, identifies a different material.
• Purity by HPLC: reversed-phase HPLC should show a single dominant peak, with the purity percentage reported for the specific batch. For an 11-mer, deletion sequences and other synthesis by-products are the impurities that matter most, and they are exactly what a chromatogram, properly run, is there to reveal.
• Sequence confirmation: mass alone establishes composition, not order. Tandem mass spectrometry or equivalent sequence-level confirmation distinguishes the specified helix-B surface sequence from a same-composition rearrangement.
• Net peptide content: lyophilized peptide material is never 100% peptide by weight; the balance is typically water and counterions from purification. A certificate reporting only a purity percentage, without net peptide content, does not state how much actual peptide a given weight of material contains — a distinction that matters in any quantitative assay.

A complete, batch-specific certificate of analysis should therefore report all three results together: purity by HPLC, identity by mass spectrometry against the expected mass, and net peptide content, each tied to the lot supplied. Our guide to reading a peptide COA walks through these checks in detail.

Handling and Storage: What the Literature Supports

ARA-290-specific stability studies are not a feature of the published record reviewed for this guide, so no compound-specific shelf life claim is made here. What can be stated is the general position for lyophilized synthetic peptides, the form in which ARA-290 research material is supplied. Freeze-drying removes the water that drives most peptide degradation pathways, so a sealed lyophilized peptide is substantially more stable than the same peptide in solution. The handling principles follow from that: keep lyophilized material sealed against moisture, protected from light, and stored cold as specified for the batch in hand; allow a sealed container to reach room temperature before opening, so moisture does not condense into the material; and treat peptide in solution as short-lived, since hydrolysis resumes in water. Researchers needing a stability claim for a specific experiment should request batch data rather than assume one from the compound's class.

Limits and Open Questions

The open questions are specific. Is the innate repair receptor a single defined complex in human tissue? Do the corneal imaging changes seen over 28 days persist, and do they predict how a patient feels or functions a year later — the surrogate-endpoint question on which the clinical case rests? Why did the largest trial's clearest structural effect appear in one group rather than increasing across groups? And can the human findings be replicated outside the developing network, at larger scale and over longer periods? Until such studies exist, ARA-290 is best described as the literature leaves it: a well-defined, rationally designed 11-amino-acid peptide, with a coherent receptor hypothesis, a supportive animal record, and a small, encouraging, unfinished human one.

Before laboratory use, verify at least 99% purity by HPLC, identity by mass spectrometry against the expected 1,257.3 Da mass, and a batch-specific certificate of analysis reporting net peptide content. NUPEPS supplies ARA-290 as a research material, with batch documentation available for review for the exact lot in hand.